Surgical management of familial pancreatic cancer: a systematic review of the literature
- PMID: 35758214
- DOI: 10.1111/ans.17834
Surgical management of familial pancreatic cancer: a systematic review of the literature
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is the third most common cause of cancer-related mortality. The fact that the vast majority of patients with PDAC are diagnosed at an advanced stage highlights the need of early diagnosis. As hereditary factors are associated with approximately 5% of all PDAC cases, a screening programme to these high-risk individuals (HRI) has been proposed. The aim of screening methods is to identify selected group of patients with morphological abnormalities at an early stage, in order to be treated promptly. In this study, we evaluate the surgical outcomes and the appropriateness of pancreatic resection in HRIs who were selected for screening.
Methods: A systematic literature search of the PubMed, Embase, and Cochrane databases was performed. The clinicopathological features were recorded and evaluated.
Results: Six studies were selected for data collection. A total number of 77 patients were identified. Twenty-one patients had a germline mutation, with CDKN2A being the most prominent one (15.6%). Distal pancreatectomy was the most common surgical procedure (42.8%), followed by pancreaticoduodenectomy (33.8%). The mean disease-free survival was 23.6 months and tumour recurrence occurred in 9 patients (11.7%). Disease-specific mortality was 17.8%, while overall mortality was 19.5%. The most frequently reported postoperative diagnosis was PDAC (28 cases, 38.9%), followed by IPMN (23 cases, 31.9%), whereas high-grade PanIN lesions were found in 13 patients (18.1%).
Conclusion: High-risk individuals for pancreatic cancer, who are eventually operated may have a relatively uneventful postoperative course, however the oncological outcomes are comparable to the general population.
Keywords: High-risk individuals; familial pancreatic cancer; hereditary syndromes; surgical resection; total pancreatectomy.
© 2022 Royal Australasian College of Surgeons.
Similar articles
-
Prophylactic mastectomy for the prevention of breast cancer.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. doi: 10.1002/14651858.CD002748.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3. PMID: 15495033 Updated.
-
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866378 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Interventions for promoting habitual exercise in people living with and beyond cancer.Cochrane Database Syst Rev. 2018 Sep 19;9(9):CD010192. doi: 10.1002/14651858.CD010192.pub3. Cochrane Database Syst Rev. 2018. PMID: 30229557 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
Cited by
-
Pancreatic Cancer: Pathogenesis and Clinical Studies.MedComm (2020). 2025 Apr 2;6(4):e70162. doi: 10.1002/mco2.70162. eCollection 2025 Apr. MedComm (2020). 2025. PMID: 40182139 Free PMC article. Review.
-
Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review.Rom J Morphol Embryol. 2022 Jul-Sep;63(3):491-502. doi: 10.47162/RJME.63.3.03. Rom J Morphol Embryol. 2022. PMID: 36588487 Free PMC article. Review.
References
-
- Surveillance E, End Results Program. http://seer.cancer.gov/.
-
- Gungor C, Hofmann BT, Wolters-Eisfeld G, Bockhorn M. Pancreatic cancer. Br. J. Pharmacol. 2014; 171: 849-58.
-
- Chang JC, Kundranda M. Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int. J. Mol. Sci. 2017; 18: E667.
-
- Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch. Pathol. Lab. Med. 2009; 133: 365-74. https://doi.org/10.1043/1543-2165-133.3.365.
-
- Canto MI, Harinck F, Hruban RH et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-47. https://doi.org/10.1136/gutjnl-2012-303108.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous